165 related articles for article (PubMed ID: 18765558)
1. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
[TBL] [Abstract][Full Text] [Related]
2. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study.
Severi G; Hayes VM; Padilla EJ; English DR; Southey MC; Sutherland RL; Hopper JL; Giles GG
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):610-2. PubMed ID: 17372260
[TBL] [Abstract][Full Text] [Related]
3. Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
Meyer A; Schürmann P; Ghahremani M; Kocak E; Brinkhaus MJ; Bremer M; Karstens JH; Hagemann J; Machtens S; Dörk T
Urol Oncol; 2009; 27(4):373-6. PubMed ID: 18625567
[TBL] [Abstract][Full Text] [Related]
4. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.
Wang L; McDonnell SK; Slusser JP; Hebbring SJ; Cunningham JM; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Res; 2007 Apr; 67(7):2944-50. PubMed ID: 17409399
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients.
Sun J; Lange EM; Isaacs SD; Liu W; Wiley KE; Lange L; Gronberg H; Duggan D; Carpten JD; Walsh PC; Xu J; Chang BL; Isaacs WB; Zheng SL
Prostate; 2008 Apr; 68(5):489-97. PubMed ID: 18213635
[TBL] [Abstract][Full Text] [Related]
6. Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer.
Levin AM; Zuhlke KA; Ray AM; Cooney KA; Douglas JA
Prostate; 2007 Oct; 67(14):1507-13. PubMed ID: 17683075
[TBL] [Abstract][Full Text] [Related]
7. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles.
Helfand BT; Loeb S; Cashy J; Meeks JJ; Thaxton CS; Han M; Catalona WJ
J Urol; 2008 Jun; 179(6):2197-201; discussion 2202. PubMed ID: 18423739
[TBL] [Abstract][Full Text] [Related]
8. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy.
Nam RK; Zhang WW; Klotz LH; Trachtenberg J; Jewett MA; Sweet J; Toi A; Teahan S; Venkateswaran V; Sugar L; Loblaw A; Siminovitch K; Narod SA
Clin Cancer Res; 2006 Nov; 12(21):6452-8. PubMed ID: 17085659
[TBL] [Abstract][Full Text] [Related]
9. The use of genetic markers to determine risk for prostate cancer at prostate biopsy.
Nam RK; Zhang WW; Jewett MA; Trachtenberg J; Klotz LH; Emami M; Sugar L; Sweet J; Toi A; Narod SA
Clin Cancer Res; 2005 Dec; 11(23):8391-7. PubMed ID: 16322300
[TBL] [Abstract][Full Text] [Related]
10. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.
Zheng SL; Sun J; Cheng Y; Li G; Hsu FC; Zhu Y; Chang BL; Liu W; Kim JW; Turner AR; Gielzak M; Yan G; Isaacs SD; Wiley KE; Sauvageot J; Chen HS; Gurganus R; Mangold LA; Trock BJ; Gronberg H; Duggan D; Carpten JD; Partin AW; Walsh PC; Xu J; Isaacs WB
J Natl Cancer Inst; 2007 Oct; 99(20):1525-33. PubMed ID: 17925536
[TBL] [Abstract][Full Text] [Related]
11. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G
Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593
[TBL] [Abstract][Full Text] [Related]
12. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome.
Sfar S; Hassen E; Saad H; Mosbah F; Chouchane L
Cytokine; 2006 Jul; 35(1-2):21-8. PubMed ID: 16908180
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.
Nam RK; Zhang WW; Trachtenberg J; Diamandis E; Toi A; Emami M; Ho M; Sweet J; Evans A; Jewett MA; Narod SA
J Clin Oncol; 2003 Jun; 21(12):2312-9. PubMed ID: 12805332
[TBL] [Abstract][Full Text] [Related]
14. Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer.
Elkins DA; Yokomizo A; Thibodeau SN; J Schaid D; Cunningham JM; Marks A; Christensen E; McDonnell SK; Slager S; J Peterson B; J Jacobsen S; R Cerhan J; L Blute M; J Tindall D; Liu W
Prostate; 2003 Jun; 56(1):30-6. PubMed ID: 12746844
[TBL] [Abstract][Full Text] [Related]
15. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus.
Kammerer S; Roth RB; Reneland R; Marnellos G; Hoyal CR; Markward NJ; Ebner F; Kiechle M; Schwarz-Boeger U; Griffiths LR; Ulbrich C; Chrobok K; Forster G; Praetorius GM; Meyer P; Rehbock J; Cantor CR; Nelson MR; Braun A
Cancer Res; 2004 Dec; 64(24):8906-10. PubMed ID: 15604251
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci.
Goode EL; Stanford JL; Peters MA; Janer M; Gibbs M; Kolb S; Badzioch MD; Hood L; Ostrander EA; Jarvik GP
Clin Cancer Res; 2001 Sep; 7(9):2739-49. PubMed ID: 11555587
[TBL] [Abstract][Full Text] [Related]
17. The evidence for prostate cancer risk loci at 8q24 grows stronger.
Savage SA; Greene MH
J Natl Cancer Inst; 2007 Oct; 99(20):1499-501. PubMed ID: 17925532
[No Abstract] [Full Text] [Related]
18. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.
Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R
Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 polymorphism is associated with more aggressive prostate cancer.
Tan D; Wu X; Hou M; Lee SO; Lou W; Wang J; Janarthan B; Nallapareddy S; Trump DL; Gao AC
J Urol; 2005 Aug; 174(2):753-6. PubMed ID: 16006970
[TBL] [Abstract][Full Text] [Related]
20. Association of a CAV-1 haplotype to familial aggressive prostate cancer.
Haeusler J; Hoegel J; Bachmann N; Herkommer K; Paiss T; Vogel W; Maier C
Prostate; 2005 Oct; 65(2):171-7. PubMed ID: 15948133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
